J. Kulisevsky

Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies
202418 citationsauthor #15
Impact of Stimulation Frequency on Verbal Fluency Following Bilateral Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.
20242 citationsauthor #6
Baseline Large‐Scale Network Dynamics Associated with Disease Progression in Huntington's Disease
20231 citationsauthor #10
Suicidal ideation among people with Parkinson's disease and comparison with a control group
20234 citationsauthor #35
Parkinson's Disease‐Cognitive Rating Scale (PD‐CRS): Normative Data and Mild Cognitive Impairment Assessment in Brazil
20236 citationsauthor #10
Lamin B1 and nuclear morphology in peripheral cells as new potential biomarkers to follow treatment response in Huntington's disease
20234 citationsauthor #6
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
20238 citationsauthor #1
Effect of istradefylline dosage on unified Parkisons’ disease rating scale (UPDRS) III-ON scores: results from four randomized clinical trials
20230 citationsauthor #1
Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints
20237 citationsauthor #36
Late‐Onset Beta‐Propeller Protein‐Associated Neurodegeneration: A Case Report
20233 citationsauthor #7
Structural and metabolic brain correlates of arithmetic word‐problem solving in Huntington's disease
20233 citationsauthor #6
Understanding visual hallucinations: a new synthesis.
202363 citationsauthor #10
Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments
20235 citationsauthor #28
Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson’s Disease
202317 citationsauthor #36
Changes in Principal Caregiver Mood Affects the Mood of the Parkinson’s Disease Patient: The Vicious Cycle of Illness
20232 citationsauthor #35
Cerebellar Syndrome Induced by Hypomagnesemia: A Treatable Cause of Ataxia Not to be Missed. Report of Three Cases and a Review of the Literature
20234 citationsauthor #6
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease
202311 citationsauthor #2
Koro-like syndrome in Huntington's disease.
20231 citationsauthor #3
Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life
20235 citationsauthor #35
Towards improved access to device-aided therapies in advanced PD: the importance of cooperation of different disciplines
20230 citationsauthor #1
Predicting Disability in Progressive Supranuclear Palsy Using Bedside Frontal‐Lobe Signs
20234 citationsauthor #5
Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group
20233 citationsauthor #34
Divergent cognitive trajectories in early stage Huntington's disease: A 3‐year longitudinal study
202310 citationsauthor #8
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
202221 citationsauthor #7
A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease
20225 citationsauthor #10
Theta/Alpha Band Suppression and Clinical Outcomes During Globus Pallidus Internus Deep Brain Stimulation in Huntington's Disease
20222 citationsauthor #10
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease
20226 citationsauthor #5
E06 Temporo-spatial structural characterization of deep white matter tracts across the spectrum of Huntington’s disease
20220 citationsauthor #5
Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders
20220 citationsauthor #3
Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease.
202221 citationsauthor #32
Theta oscillations and minor hallucinations in Parkinson’s disease reveal decrease in frontal lobe functions and later cognitive decline
202211 citationsauthor #5
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data
20220 citationsauthor #14
Trial of Deferiprone in Parkinson's Disease.
2022144 citationsauthor #31
Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert
202218 citationsauthor #1
Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
202226 citationsauthor #15
Genotype–Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities
20225 citationsauthor #4
Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration
202232 citationsauthor #11
Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers
20228 citationsauthor #9
Delineating apathy profiles in Huntington's disease with the short-Lille Apathy Rating Scale.
20225 citationsauthor #5
The role of attentional control over interference in minor hallucinations in Parkinson's disease.
20224 citationsauthor #12
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data
202219 citationsauthor #14
An MDS Evidence‐Based Review on Treatments for Huntington's Disease
202236 citationsauthor #11
Smoking is associated with age at disease onset in Parkinson's disease.
20225 citationsauthor #44
D20 Altered levels of brain extracellular vesicle subpopulations in Huntington’s disease
20220 citationsauthor #7
Reduplicative paramnesia as an atypical form of presentation of a Heidenhain variant of Creutzfeldt-Jakob disease: A case report
20220 citationsauthor #5
Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study
20229 citationsauthor #37
Clinical and structural brain correlates of hypomimia in early‐stage Parkinson's disease
20227 citationsauthor #33
Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson's disease.
20227 citationsauthor #7
Associations Between Diabetic Retinopathy and Parkinson's Disease: Results From the Catalonian Primary Care Cohort Study
202210 citationsauthor #6
A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
202217 citationsauthor #1
Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients
202214 citationsauthor #38
Response to letter: "Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson's disease".
20220 citationsauthor #3
Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington’s Disease
20226 citationsauthor #13
Measuring the functional impact of cognitive impairment in Huntington’s disease
20227 citationsauthor #7
D10 Plasma extracellular small RNAS are early deregulated in Huntington’s disease and correlate with cognitive symptoms
20220 citationsauthor #5
Intracortical surface‐based MR diffusivity to investigate neurologic and psychiatric disorders: a review
202112 citationsauthor #2
Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease
202117 citationsauthor #44
Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study
20210 citationsauthor #5
Structure and Dynamics of Large‐Scale Cognitive Networks in Huntington's Disease
202114 citationsauthor #11
MNCD: A New Tool for Classifying Parkinson’s Disease in Daily Clinical Practice
20218 citationsauthor #8
E08 Tracking the neurodegeneration pattern of the anterior thalamic radiations in HD: a focus on brain iron, white matter integrity and metabolites
20210 citationsauthor #5
F24 Unsupervised clustering reveals longitudinal psychiatric signatures in HD
20210 citationsauthor #8
Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
202111 citationsauthor #8
Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up
20213 citationsauthor #37
Falls Predict Acute Hospitalization in Parkinson’s Disease
202112 citationsauthor #49
Identification of sixteen novel candidate genes for late onset Parkinson’s disease
202171 citationsauthor #120
Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group
202120 citationsauthor #38
Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntington’s Disease
20212 citationsauthor #28
Predictors of clinically significant quality of life impairment in Parkinson’s disease
202133 citationsauthor #38
Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis.
202134 citationsauthor #13
Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.
20217 citationsauthor #14
Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
20210 citationsauthor #8
Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage
202112 citationsauthor #112
The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?
202114 citationsauthor #6
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
20210 citationsauthor #2
Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson’s disease mild cognitive impairment
20218 citationsauthor #15
Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease
202156 citationsauthor #159
Is COVID-19 Expansion a Consequence of a Group Inaction?
20211 citationsauthor #2
Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease.
202117 citationsauthor #10
F40 Proof-of-concept study testing SOM3355, a VMAT2 inhibitor for the treatment of chorea in huntington’s disease
20210 citationsauthor #10
Predictors of clinically significant quality of life impairment in Parkinson’s disease
20210 citationsauthor #38
Cognitive and Affective Empathy in Huntington’s Disease
20218 citationsauthor #10
Parkinson’s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up
20218 citationsauthor #36
Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life
202119 citationsauthor #37
Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network
202138 citationsauthor #22
Predictors of Loss of Functional Independence in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group
202115 citationsauthor #36
In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
202123 citationsauthor #25
Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease
202113 citationsauthor #6
Correction to: Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease
20210 citationsauthor #27
Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up
202114 citationsauthor #38
Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes
202127 citationsauthor #12
The Parkinson’s Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations
20213 citationsauthor #7
Sensorimotor hallucinations in Parkinson’s disease
20203 citationsauthor #22
Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease.
202012 citationsauthor #9
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
202039 citationsauthor #2
Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information
202026 citationsauthor #112
Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176
20201 citationsauthor #8
The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
202035 citationsauthor #16
Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease
20209 citationsauthor #3
Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa
202011 citationsauthor #1

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT